# CURRICULUM VITAE

## Name: Angeliki Magklara

**Contact Information:**

**Telephone**: +30-26510-07818 (office), +30-26510-09032 (lab)

**E-mail address**: magklara@uoi.gr

**Current positions:**

- Associate Professor of Clinical Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
- Scientific responsible for the Unit of Liquid Biopsies (Biochemistry Laboratory- Section of Molecular Diagnostics) at the University Hospital of Ioannina.
- Affiliated Researcher and Group Leader at the Biomedical Research Institute-Foundation for Research and Technology, Hellas.
- Affiliated Researcher with the Institute of Biosciences, University Center of Ioannina.

## I. EDUCATION-DEGREES

*June 2003:* **PhD in Clinical Biochemistry**
Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Canada.

*October 1997:* **Master of Science in Clinical Chemistry-Clinical Biochemistry**
Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece.

*November 1994:* **Bachelor of Science in Biology**
Department of Biology, National and Kapodistrian University of Athens, Athens, Greece.

## II. PREVIOUS POSITIONS HELD

*October 2018- April 2019*: **Visiting Scientist**,
Whitehead Institute, MIT, Cambridge, USA.

*December 2013-September 2015*: **Lecturer of Clinical Chemistry.**
School of Medicine, University of Ioannina, Ioannina, Greece.

*January 2008- August 2012* : **Post-doctoral research associate.**
Department of Anatomy, University of California in San Francisco, San Francisco, CA, USA (Laboratory of Dr. Stavros Lomvardas).

*April 2003- December 2007* : **Post-doctoral fellow.**
Laboratory of Receptor Biology and Gene Expression, NCI/NIH, Bethesda, MD, USA (research advisor: Dr. Catharine L. Smith).

*September 1998-April 2003* : **PhD candidate.**
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (research advisor: Dr. E. P. Diamandis)

## III. OTHER RESEARCH TRAINING

- Five-day training on BEAMing Digital PCR. June 26-30, 2017, Sysmex training center, Barcelona, Spain.
- Three-day workshop organized by the Epigenome project on the use of bioinformatics on the processing of epigenetics data. September 10-12, 2009, Baylor College of Medicine, Houston Texas USA.
- Five-day workshop organized by the Foundation for Advanced Education in Sciences (FAES-NIH) on "Stem Cells" (lectures and lab work). October 15-19, 2007, Bethesda, MD, USA.
- Various seminars organized by the National Center for Biotechnology Information (NCBI/NIH) on the use of bioinformatics tools developed by NCBI (2003-2007, NIH campus, Bethesda Maryland, USA).
- Three-week course (lectures and lab work) on “Eukaryotic Gene Expression” organized by the Cold Spring Harbor Laboratory, NY USA (27 July-16 August 2004).
- One month training on protein microarrays at the Genomics Institute of the Novartis Research Foundation, La Jolla CA, USA (November-December 2002).
- Three-day workshop on cDNA microarrays at the Microarray Center of Ontario Cancer Institute, Toronto, Canada, 2000.

## IV. FELLOWSHIPS and AWARDS

- Fulbright scholarship for visiting scholars (Whitehead Institute-MIT, USA).
- University of Toronto Open Doctoral Fellowship, Canada.
- Differential Fee Waiver for International Students, University of Toronto, Canada.
- Fellowship from the Greek-Canadian association for graduate studies in Canada.

## V. PUBLICATIONS

1. Iatridis N, Kougioumtzi A, Vlataki K, Papadaki S, **Magklara A**. Anti-Cancer Properties of Stevia rebaudiana; More than a Sweetener. ***Molecules***.2022;27(4):1362. doi: 10.3390/molecules27041362.
2. Kastrisiou M, Zarkavelis G, Kougioumtzi A, Sakaloglou P, Kostoulas C, Georgiou I, Batistatou A, Pentheroudakis G, **Magklara A**. Development and Validation of a Targeted 'Liquid' NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer. ***Diagnostics (Basel).*** 2021;11(12):2375. doi: 10.3390/diagnostics11122375.
3. Verigos J, Kordias D, Papadaki S, **Magklara A**. Transcriptional Profiling of Tumorspheres Reveals TRPM4 as a Novel Stemness Regulator in Breast Cancer. ***Biomedicines.*** 2021;9(10):1368. doi: 10.3390/biomedicines9101368.
4. Tsolis T, Nikolaou N, Ypsilantis K, Kougioumtzi A, Kordias D, **Magklara A**, Garoufis A. Synthesis, characterization, interactions with 9-MeG and cytotoxic activity of heterobimetallic RuII-PtII complexes bridged with 2, 2'-bipyrimidine. ***J Inorg Biochem***. 2021;219:111435.
5. Verigos J, Karakaidos P, Kordias D, Papoudou-Bai A, Evangelou Z, Harissis HV, Klinakis A, **Magklara A**. The Histone Demethylase LSD1/KDM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program. ***Cancers (Basel)***. 2019;11(10).
6. Karakaidos P, Verigos J, **Magklara A**.LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target***. Cancers (Basel);*** 11(12), 2019.
7. Kastrisiou M, Zarkavelis G, Pentheroudakis G, **Magklara A**. Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat? ***Cancers (Basel)***. 2019 Oct 16;11(10).
8. Touloupi K, Küblbeck J, **Magklara A**, Molnár F, Reinisalo M, Konstandi, Honkakoski P, Pappas P The basis for strain-dependent rat aldehyde dehydrogenase 1A7 (ALDH1A7) gene expression. ***Molecular Pharmacology*** 2019; 96(5), 655-663.
9. Le Gros MA, Clowney EJ, **Magklara A**, Yen A, Markenscoff-Papadimitriou E, Colquitt B, Myllys M, Kellis M, Lomvardas S, Larabell CA. Soft X-Ray Tomography Reveals Gradual Chromatin

Compaction and Reorganization during Neurogenesis In Vivo. ***Cell Rep***. 2016 Nov 15;17(8):2125-2136.

10. Verigos J and **Magklara A**: Revealing the Complexity of Breast Cancer by Next Generation Sequencing. ***Cancers (Basel)*** 2015;7(4):2183-200.
11. Lyons DB, **Magklara A**, Goh T, Sampath S, Schaefer A, Schotta G, Lomvardas S. Heterochromatin-Mediated Gene Silencing Facilitates the Diversification of Olfactory Neurons. ***Cell Rep***.2014;9:1-9.
12. Kougioumtzi A, Tsaparas P, **Magklara A**. Deep sequencing reveals new aspects of progesterone receptor signaling in breast cancer cells. ***PLoS One***. 2014 Jun 4;9(6):e98404.
13. **Magklara A** and Lomvardas S: Stochastic gene expression in mammals: Lessons from Olfaction. ***Trends in Cell Biology*** 2013 Sep;23(9):449-56.
14. Johnson MA, Tsai L, Roy DS, Valenzuela DH, Mosley C, **Magklara A**, Lomvardas S, Liberles SD, Barnea G. Neurons expressing trace amine-associated receptors project to discrete glomeruli and constitute an olfactory subsystem. ***Proc Natl Acad Sci U S A***. 2012 Aug 14;109(33):13410-5.
15. Clowney EJ, **Magklara A**, Colquitt BM, Pathak N, Lane RP, Lomvardas S. High-throughput mapping of the promoters of the mouse olfactory receptor genes reveals a new type of mammalian promoter and provides insight into olfactory receptor gene regulation. ***Genome Res***. 2011 Aug;21(8):1249-59
16. **Magklara A**, Yen A, Colquitt BM, Clowney EJ, Allen W, Markenscoff-Papadimitriou E, Evans ZA, Kheradpour P, Mountoufaris G, Carey C, Barnea G, Kellis M, Lomvardas S. An epigenetic signature for monoallelic olfactory receptor expression. ***Cell***. 2011 May 13;145(4):555-70.
17. Lee SC, **Magklara A**, Smith CL. HDAC activity is required for efficient core promoter function at the mouse mammary tumor virus promoter. ***J Biomed Biotechnol***. 2011;2011:416905
18. **Magklara A**, Smith CL. A composite intronic element directs dynamic binding of the progesterone receptor and GATA-2. ***Mol Endocrinol***. 2009;23:61-73.
19. Michael IP, Sotiropoulou G, Pampalakis G, **Magklara A**, Ghosh M, Wasney G, Diamandis EP. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. ***J Biol Chem***. 2005;280:14628-35.
20. Yousef GM, Obiezu CV, Luo LY, **Magklara A**, Borgoño CA, Kishi K, Memari N, Michael IP, Sidiropoulos M, Kurlender L, Economopoulou K, Kapadia C, Komatsu N, Petraki C, Elliott M, Scorilas A, Katsaros D, Levesque1 MA, Diamandis EP. Human Tissue Kallikreins: From Gene Structure to Function and Clinical Applications. ***Adv Clin Chem*** 2005;39:11-79.
21. Sauter ER, Lininger J, **Magklara A**, Hewett JE, Diamandis EP. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. ***Int J Cancer***. 2004;108:588-91.
22. Kapadia C, Yousef GM, Mellati AA, **Magklara A**, Wasney GA, Diamandis EP. Complex formation between human kallikrein 13 and serum protease inhibitors. ***Clin Chim Acta*** 2004;339:157-67.

23. **Magklara A**, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, Diamandis EP. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. ***Biochem Biophys Res Commun***. 2003;307:948-55.

24. Yousef GM, Scorilas A, **Magklara A**, Memari N, Ponzone R, Sismondi P, Abd Ellatif M, and Diamandis EP. The androgen regulated gene human kallikrein 15 (KLK15) is an independent and favorable prognostic marker for breast cancer. ***Br J Cancer*** 2002;87:1294-300.

25. Sauter ER, Welch T, **Magklara A**, Klein G, Diamandis EP. Ethnic variation in kallikrein expression in nipple aspirate fluid. ***Int J Cancer***. 2002 ;100:678-82.

26. **Magklara A**, Brown TJ and Diamandis EP. Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. ***Int J Cancer***.2002;100: 507-14.

27. **Magklara A**, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP. The human KLK8 (neuropsin/ovasin) gene: Identification of two novel slice variants and its prognostic value in ovarian cancer. ***Clin Cancer Res***. 2001;7:806-11.

28. Scorilas A, **Magklara A**, Hoffman BR, Bromberg RM, Bjartell A and Diamandis EP. Highly sensitive array analysis using time resolved fluorescence and a novel streptavidin-based reagent. ***Analytical Sciences*** 2001;17(suppl):i547-i551.

29. Yousef GM, **Magklara A** and Diamandis EP. Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies ***Cancer Res***. 2001;61:3425-31.

30. Obiezu CV, Scorilas A, **Magklara A**, Thornton MH, Wang CY, Stanczyk FZ, Diamandis EP. Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. ***J Clin Endocrinol Metab*** 2001;86:1558-61.

31. Yousef GM, **Magklara A** and Diamandis EP. KLK12 is a novel serine protease and a new member of the human kallikrein gene family- Differential expression in breast cancer. ***Genomics***, 2000;69:331-41.

32. Yousef GM, Scorilas A, **Magklara A**, Soosaipillai A, Diamandis EP. The PRSS6 gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family-genomic characterization, mapping, tissue expression and hormonal regulation. ***Gene***, 2000;254:119-128.

33. **Magklara A**, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K and Diamandis EP. Decreased concentrations of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) in malignant vs non-malignant prostatic tissue. ***Urology***, 2000;56:527-32.

34. **Magklara A**, Cheung CC, Asa SL, Diamandis EP. Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. ***Clinica Chimica Acta***, 2000;300:171-80.

35. Obiezu CV, Giltay EJ, **Magklara A**, Scorilas A, Gooren L, Yu H, Diamandis EP. Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals**.** ***J Urol*** 2000;163:802-5.
36. Diamandis EP, Yousef GM, Luo LY, **Magklara A** and Obiezu CV. The new human kallikrein gene family-implications in carcinogenesis. ***Trend Endocrinol Metab*** 2000;11:54-60.
37. Obiezu CV, Giltay EJ, **Magklara A**, Scorilas A, Gooren L, Yu H, Howarth DJC and Diamandis EP. Serum and urinary prostate specific antigen and urinary human glandular kallikrein concentration are significantly elevated after testosterone administration in female to male transsexuals. ***Clinical Chemistry*** 2000;46:859-862.
38. Zand Rosenberg RS, Grass L, **Magklara A**, Jenkins DJA and Diamandis EP. Is ICI 182-780 an anti-progestin in addition to being an anti-estrogen? ***Breast Cancer Res Treat*** 2000;60:1-8.
39. **Magklara A**, Grass L, Diamandis EP. Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate specific antigen (PSA) in breast cancer cell lines. ***Breast Cancer Res Treat*** 2000;59:263-70.
40. Nam RK, Diamandis EP, Toi A, Trachtenberg J, **Magklara A**, Scorilas A, Papanastasiou PA, Jewett MAS and Narod SA. Serum human glandular kallikrein (hK2) protease levels predict the presence of prostate cancer among men with elevated prostate specific-antigen. ***Journal of Clinical Oncology*** 2000;18:1036-42.
41. Black MH, **Magklara A**, Obiezu CV, Levesque MA, Sutherland DJA, Tindall DJ, Young CYF, Sauter ER, Diamandis EP. Expression of a prostate associated protein, human glandular kallikrein (hK2) in breast tumors and in normal breast secretions. ***Br J Cancer*** 2000;82:361-7.
42. **Magklara A**, Scorilas A, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein (hK2) and free PSA enhances the discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately elevated total PSA levels. ***Clinical Chemistry*** 1999;45:1960-6.
43. **Magklara A**, Scorilas A, López-Otín C, Diamandis EP. Human glandular kallikrein (hK2) in breast milk, amniotic fluid and breast cyst fluid. ***Clinical Chemistry***, 1999;45:1774-80.
44. Black MH, **Magklara A**, Obiezu CV, Melegos DN, Diamandis EP. Development of an ultrasensitive immunoassay for human glandular kallikrein (hK2) with no cross reactivity from prostate specific antigen (PSA). ***Clinical Chemistry*** 1999;45:790-9.

## VI. BOOK CHAPTERS

1. **Angeliki Magklara** and Stavros Lomvardas: Epigenetics and Human Disease. "Gene Regulatory Sequences and Human Disease", editor Nadav Ahituv, Springer New York 2012.

## VII. EDITOR AND REVIEWER IN SCIENTIFIC JOURNALS

- Guest Academic Editor of the Special Issues: " Epigenetic Dysregulation in Cancer: From Mechanism to Therapy" and "Metabolic Reprogramming of Cancer Stem Cells (CSCs) and the Role of Tumor Microenvironment—Mechanisms and Therapeutic Opportunities" in the journal *Cancers (Basel).*
- Member of the editorial board of *Cancers (Basel)*
- Reviewer for: BMC Cancer, Tumor biology, PlosOne, Molecular and Cellular Endocrinology, European Journal of Pharmacology, Nanomaterials, Applied Biosciences, Biomedicines, Cancer Chemotherapy and Pharmacology, Clinical Chemistry and Laboratory Medicine, Experimental and Molecular Medicine, International Journal of Molecular Science, Theranostics, Current Issues in Molecular Biology, Genes

## VIII. RESEARCH GRANTS

| Project Title | Funding source | Period | Role of the PI |
|---|---|---|---|
| Understanding pathways of healthy ageing (in health and disease) through integration of high resolution omics data (pathAGE). (MIS 5047228) | Hellenic Ministry of Development and Investments (ESPA 2014-2020) | 2020-2023 | Participant |
| Development of new infrastructure that builds “aptitude” in biomedical research (BIOMED-20) (MIS 5047236) | Hellenic Ministry of Development and Investments (ESPA 2014-2020) | 2020-2023 | Participant |
| Investigation of the gene networks regulated by histone demethylase LSD1 in breast CSCs. | ELKE (Research Committee of University of Ioannina) | 03/2020-09/2020 | Supervisor |
| Optical analytical platform for large-scale heterogeneous biodata (T2EΔK-00407) | Research-Create-Innovate 2nd round (ESPA 2014-2020) | 2020-2023 | Participant-Scientific Responsible for the Univ. of Ioannina |
| Development of probiotic-enriched food products incorporated in prebiotic matrices (MIS 5049149) | Bilateral and Multilateral R&T Greece-China Co-operation (ESPA 2014-2020) | 10.2019-09.2022 | Participant-Scientific Responsible for FORTH-IMBB |

| | | | |
|---|---|---|---|
| Holistic Approach along the production cycle of Stevia Rebaudiana plant cultivated in Greece, via combined application of innovative methods of Precision Agriculture and bitter aftertaste removal techniques (MIS 5031858) | Research-Create-Innovate 1st round (ESPA 2014-2020) | 08.2018-07.2021 | Participant-Scientific Responsible for FORTH-IMBB |
| Study of epigenetic mechanisms in breast cancer stem cells | SNF (ARCHERS) - FORTH fellowships for PhD candidates | 01.2019-12.2019 | Supervisor |
| The role of epigenetic mechanisms of regulation of gene expression in breast cancer heterogeneity - Prospects for targeted therapies (MIS 5004375) | Supporting researchers with an emphasis on young researchers (EDBM34) (ESPA 2014-2020) | 11.2018-02.2020 | Scientific Responsible |
| Advanced Research Activities in Biomedical Technology-Epirus (MIS 5002469) | Operational Programme Competitiveness, Entrepre-neurship and Innovation 2014-2020 | 10.2017-09.2020 | Participant |
| Isolation and characterization of breast cancer stem cells | IKY Scholarships for PhD students. | 05.2017-12.2018 | Supervisor |
| Study of LSD1 in mammary cancer stem cells | SNF (ARCHERS) - FORTH fellowships for post-doctoral fellows | 06.2017-05.2018 | Supervisor |
| Deciphering the role of histone demethylase LSD1 in the epigenetic dynamics of breast Cancer Stem Cells | Fondation Sante Biomedical Research Grants. | 03.2017-02.2019 | Scientific Responsible |
| The role of histone demethylase LSD1 in breast cancer | Bodossaki Foundation grants for Biomedical Sciences | 2015-2016 | Scientific Responsible |
| The Epigenome of Breast Cancer Stem Cells (PCIG10-GA-2011-303519) | Marie Curie Re-Integration Grants. | 2012-2016 | Principal Investigator |

## IX. PRESENTATIONS AT INTERNATIONAL CONFERENCES

1. Kastrisiou M, Zarkavelis G, Kougioumtzi A, Tzallas C, Tselikou E, Mantziou A, Papadopoulou E, Nasioulas G, Batistatou A, **Magklara A**, Pentheroudakis G. Clinical validation of Next-Generation Sequencing as a liquid biopsy for the monitoring of patients with metastatic colorectal cancer. *ESMO 22nd World Congress on Gastrointestinal cancer* (virtual conference) 1-4 July 2020.
2. Gkoura S, Kastrisiou M, Kougioumtzi A, Tzallas C, Gkrepi K, Goussia A, **Magklara A**, Pentheroudakis G. Role of detection and quantification of plasma ctDNA RAS mutations by BEAMing digital PCR in patients with locally advanced and metastatic pancreatic cancer. *ESMO 22nd World Congress on Gastrointestinal cancer* (virtual conference) 1-4 July 2020.
3. Gkoura S, Kastrisiou M, Kougioumtzi A, Tzallas C, Gkrepi K, Goussia A, **Magklara A**, Pentheroudakis G. Plasma ctDNA *RAS* mutation analysis by digital polymerase chain reaction in patients with inoperable pancreatic cancer. *ESMO Molecular Analysis for Personalised Therapy*, London, UK, 7-9 November 2019. **Published in Annals of Oncology 30 (Supplement_7).**
4. Kastrisiou M, Zarkavelis G, Kougioumtzi A, Tzallas C, Saloustros E, Kotsakis A, Papadopoulou E, Nasioulas G, Batistatou A, **Magklara A**, Pentheroudakis G. Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: updated results of an observational study. *ESMO Molecular Analysis for Personalised Therapy*, London, UK, 7-9 November 2019. **Published in Annals of Oncology 30, vii13**.
5. Verigos J, Karakaidos P, **Magklara A**. The histone demethylase LSD1 mediates chemoresistance in breast cancer via induction of a stem cell programme. *Epigenomics of Common Diseases*, Wellcome Genome Campus, Hinxton, Cambridge, UK, 6-8 November 2019 **(selected for short talk)**.
6. Kastrisiou M, Zarkavelis G, Tzallas C, Gkrepi K, Batistatou A, **Magklara A**, Pentheroudakis G. Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: preliminary results of an observational study. *EACR-ESMO Joint Conference on Liquid Biopsies* Bergamo, Italy, 15-17 May 2019.
7. Verigos J, Mitrentsi I, Angeloni V, Mantzaris MD, Daidone MG and **Magklara A.** Elucidating the role of histone demethylase LSD1 (KDM1A) in breast cancer stem cells. *6th Clinical Epigenetics International Meeting*, Dusseldorf, Germany, 3-4 March 2016.
8. **Magklara A**, Colquitt BM, Clowney EJ, Yen A, Allen W, Markenscoff-Papadimitriou E, Kheradpour P, Mountoufaris G, Carey C, Barnea G, Kellis M and Lomvardas S. Developmental regulation of the epigenetic silencing of the olfactory receptor genes in the olfactory epithelium. *Epigenetics in development and Disease*, Miami, FL, USA, February 2011.
9. Yen, A., **Magklara, A.**, Clowney, E., Lomvardas, S. Kellis, M. Computational analysis of epigenomic modifications associated with Olfactory Receptor genes in Mus musculus. *RECOMB Satellite Conference on Regulatory Genomics*, NYC, NY, USA, November 2010.
10. Smith, C.L., **Magklara, A**., Jackson, J., and Hardwick, R. Progesterone receptor cooperates with GATA2 at an intronic element to activate the FKBP5 gene. *FASEB Summer Conference on Extra-Nuclear Steroid Receptors: Integration with Multiple Signaling Pathways*, Carefree AZ, USA July 27-August 1 2008 (poster award).
11. **Magklara A**, Smith CL. GATA-2 binding to a downstream region is necessary for the progesterone receptor regulation of Fkbp5, a natural target gene. 89th a*nnual meeting of the Endocrine Society*, Toronto, Canada, 2-5 June 2007.
12. **Magklara A**, Smith CL. Progesterone receptor action on a natural target promoter. *FASEB meeting "Chromatin and transcription"*, Snowmass CO, USA, July 9-14, 2005.

13. **Magklara A**, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, and Diamandis EP. Characterization of the enzymatic activity of human kallikrein 6 (hK6/zyme) and regulation by inhibitors. *94th meeting of the American Association for Cancer Research*, Washington DC, USA, 11-14 July 2003.
14. Yousef GM, **Magklara A**, Borgono C, Memari N, Abd-Ellatif M, Grass L and Diamandis EP. Regulation of the human kallikrein gene 15 (KLK15) by steroids in breast cancer cell lines. *93rd meeting of the American Association for Cancer Research*, San Francisco, CA, USA 6-10 April 2002.
15. **Magklara A**, Brown TJ and Diamandis EP. Characterization of androgen receptor and co-factor expression in human breast cancer cell lines. 83rd a*nnual meeting of the Endocrine Society*, Denver, CO, USA, 20-23 June 2001.
16. **Magklara A**, Scorilas A, Katsaros D, Fracchioli S, Rigault de la Longrais I, Piccino R, Yousef GM and Diamandis EP. The prognostic value of human KLK8 (neuropsin/ovasin) in ovarian cancer and evidence of alternative splicing. *92nd meeting of the American Association for Cancer Research*, New Orleans, LO, USA, 24-28 March 2001.
17. Yousef GM, **Magklara A**, Chang A, Jung K, Katsaros D and Diamandis EP. Down regulation of a novel human kallikrein gene KLK14, in endocrine related cancers. *92nd meeting of the American Association for Cancer Research*, New Orleans, LO, USA, 24-28 March 2001.
18. Diamandis EP, **Magklara A**, Scorilas A, Catalona WJ. Prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2): two hormonally regulated kallikreins with applications in breast and prostate cancer. *11th International Congress of Endocrinology*, Sydney Australia, October 29-November 2 2000.
19. Yousef GM, **Magklara A**, Diamandis EP. KLK-L5 is a new, hormonally regulated, member of the kallikrein gene family. *82nd a**nnual meeting of the Endocrine Society*, Toronto, ON Canada, 21-24 June 2000.
20. Chang A, Yousef GM, **Magklara A**, Diamandis EP. Hormonal regulation of a novel kallikrein-like gene, KLK-L4, in breast cancer. *82nd a**nnual meeting of the Endocrine Society*, Toronto, ON Canada, 21-24 June 2000.
21. **Magklara A**, Cheung CC, Asa SL, Diamandis EP. Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. *82nd a**nnual meeting of the Endocrine Society*, Toronto, ON Canada, 21-24 June 2000.
22. Yousef GM, Foussias G, **Magklara A**, Grass L, Diamandis EP. Cloning of KLK-L5, a new member of the kallikrein gene family and its hormonal regulation in breast cancer cell lines. *91st meeting of the American Association for Cancer Research*, San Francisco, CA, USA, 1-5 April 2000.
23. **Magklara A,** Scorilas A, Catalona WJ, Diamandis EP. Human glandular kallikrein (hK2) and prostate specific antigen (PSA) in prostate and breast cancer. *91st meeting of the American Association for Cancer Research*, San Francisco, CA, USA, 1-5 April 2000.
24. **Magklara A**, Scorilas A, Catalona WJ, Diamandis EP. The ratio of human glandular kallikrein (hK2) to free PSA improves the discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately elevated total PSA levels. *Molecular targets and Cancer therapeutics, AACR-NCI-EORTC International Conference*, Washington DC, USA, 16-19 November 1999.
25. Obiezu CV, Black MH, **Magklara A**, Levesque MA, Sutherland DJA, Tindall DJ, Young CYF, Sauter ER, and Diamandis EP. Expression of a prostate-associated protein, human glandular kallikrein 2 (hK2), in breast tumors and in normal breast secretions. *90th meeting of the American Association for Cancer Research*, Philadelphia PA, USA, April 10-14 1999.
26. **Magklara A**, Black MH, Obiezu CV, Melegos DN, Diamandis EP. Development of an ultrasensitive immunoassay for human glandular kallikrein (hK2) with no cross reactivity from prostate specific

antigen (PSA). *90th meeting of the American Association for Cancer Research*, Philadelphia PA, USA, April 10-14 1999.

## X. PRESENTATIONS AT NATIONAL CONFERENCES

1. Κουγιουμτζή Α., Καστρισίου Μ., Σακάλογλου Π., Ζαρκαβέλης Γ., Γεωργίου Ι., Μπατιστάτου Α., Πενθερουδάκης Γ., **Μαγκλάρα Α**. Ανάλυση ctDNA μέσω στοχευμένου NGS γονιδιακού πάνελ σε ασθενείς με μεταστατικό καρκίνο παχέος εντέρου. *19ο Πανελλήνιο Συνέδριο Κλινικής Χημείας*, Αθήνα, 4-6 Νοεμβρίου 2021. (υβριδικό συνέδριο)
2. Καστρισίου Μ., Ζαρκαβέλης Γ., Κουγιουμτζή Α., Τζάλλας Χ., Σαλούστρος Ε., Κωτσάκης Α., Μπατιστάτου Α., Πενθερουδάκης Γ., **Μαγκλάρα Α**. Μελέτη παρατήρησης της κλινικής χρησιμότητας της ανίχνευσης μεταλλάξεων *RAS* στο ctDNA ασθενών με μεταστατικό καρκίνο παχέος εντέρου/ορθού με ψηφιακή PCR. *17ο Πανελλήνιο Συνέδριο Κλινικής Χημείας*, Αθήνα, 21-23 Νοεμβρίου 2019.
3. Γκούρα Σ, Κουγιουμτζή Α., Καστρισίου Μ., Τζάλλας Χ., Νίκου Π., Γκρέπη Κ., Γούσια Α., Πενθερουδάκης Γ, **Μαγκλάρα Α.** Μελέτη των *RAS* μεταλλάξεων στο κυκλοφορούν νεοπλασματικό DNA (ctDNA) μέσω ψηφιακής PCR ως προβλεπτικού δείκτη στο μη χειρουργήσιμο καρκίνο παγκρέατος. *17ο Πανελλήνιο Συνέδριο Κλινικής Χημείας*, Αθήνα, 21-23 Νοεμβρίου 2019.
4. Καστρισίου Μ., Ζαρκαβέλης Γ., Τζάλλας Χ., Πετράκης Δ., Κωσταδήμα Λ., Τσελίκου Ε., Μάντζιου Α., Σαλούστρος Ε., Κωτσάκης Α., Παπαδοπούλου Ε., Νασιούλας Γ., **Μαγκλάρα Α**., Πενθερουδάκης Γ. Εξατομίκευση της θεραπευτικής στρατηγικής στον μεταστατικό ορθοκολικό καρκίνο μέσω υγρών βιοψιών (ανίχνευση μεταλλάξεων RAS με ψηφιακή PCR και NGS). *25ο Συνέδριο Κλινικής Ογκολογίας*, Αθήνα, 18 – 20 Απριλίου 2019.
5. Καστρισίου Μ., Τζάλλας Χ., Πενθερουδάκης Γ., **Μαγκλάρα Α.** Μοριακός έλεγχος μεταλλάξεων *RAS* στο πλάσμα ασθενών με μη χειρουργήσιμο παγκρεατικό καρκίνο μέσω υγρών βιοψιών (ψηφιακή PCR) και κλινικές εφαρμογές στην εξατομίκευση της θεραπείας. *16ο Πανελλήνιο Συνέδριο Κλινικής Χημείας*, Αλεξανδρούπολη, 11-13 Οκτώβρη 2018 **(επιλέχθηκε για προφορική ομιλία).**
6. Verigos I. Kordias D., **Magklara A**. Epigenetic regulation of breast cancer stem cell properties. *69th Conference of the Greek Society for Biochemistry and Molecular Biology*, Larissa, Greece, November 23-25, 2018.
7. Verigos J., Karakaidos P., Klinakis A., **Magklara A**. Epigenetic drugs as a new therapeutic approach for targeting Breast Cancer Stem Cells. *69th Conference of the Greek Society for Biochemistry and Molecular Biology*, Larissa, Greece, November 23-25, 2018 **(oral presentation award)**
8. Verigos I. Kordias D., **Magklara A.** Histone Demethylase LSD1 is a therapeutic target in breast cancer stem cells. *10th Conference of the Greek Society for Basic and Clinical Pharmacology*, Ioannina, Greece, May 25-27, 2018.
9. Πετράκης Δ., Γεωργόπουλος Χ., Παπαδάκη Α., Ζαφείρη Γ., Ζαρκαβέλης Γ., Πολίτη Α., Τσελίκου Ε., Μάντζιου Α., Μπατιστάτου Α., **Μαγκλάρα Α.**, Πενθερουδάκης Γ. Ανίχνευση μεταλλάξεων EGFR σε ελεύθερο νεοπλασματικό DNA πλάσματος σε ασθενείς με προχωρημένο μη μικροκυτταρικό καρκίνο πνεύμονα (ΜΜΚΠ) και απουσία ιστού: Μία αναδρομική σειρά ασθενών της Πανεπιστημιακής Ογκολογικής Κλινικής ΠΓΝ Ιωαννίνων. *4ο Ελληνικό Συνέδριο Ογκολογίας*, Θεσσαλονίκη, 3-5 Μαΐου 2018.
10. Verigos I., Mantzaris MD, **Magklara A**. The histone demethylase LSD1 is a potential drug target in breast cancer stem cells. *67th Conference of the Greek Society for Biochemistry and Molecular Biology*, Ioannina, November 25-27, 2016.

11. Verigos I., **Magklara A**. Targeting breast cancer stem cells with epigenetic drugs. *14th Greek Conference of Clinical Chemistry*, Ioannina, September 29-October 1, 2016.
12. Kostara C., Verigos I, Mitrentsi I, Kazeloglou C, Bairaktari E, **Magklara A**. Differential lipid profile between breast cancer stem and non-stem cells. *14th Greek Conference of Clinical Chemistry*, Ioannina, September 29-October 1 2016.
13. Kyrkou A., Zarkavelis G., Pentheroudakis G., **Magklara A**. Development of a highly sensitive RT-PCR for the detection of KRAS C.35G>A mutation in platelet- resorbed RNA in patients with metastatic colorectal cancer. *14th Greek Conference of Clinical Chemistry*, Ioannina, September 29-October 1 2016.

## XI. INVITED LECTURES

1. Χρήση αλληλούχισης επόμενης γενιάς (NGS) για την εξατομίκευση της θεραπείας στην Αιματολογία και Ογκολογία. 10ο Σεμινάριο Αιματολογίας, 22-24 Οκτωβρίου 2021, Ιωάννινα (υβριδικό συνέδριο).
2. NGS: Αρχές και ροή εργασίας. Επιλογή της μεθόδου ανάλυσης.27ο Ελληνικό Συνέδριο Κλινικής Ογκολογίας , 13-15 Μαΐου 2021 Αθήνα (υβριδικό συνέδριο).
3. The role of the histone demethylase LSD1 in breast Cancer Stem Cells. Laboratory of Dr. R.A. Weinberg, Whitehead Institute-MIT, Cambridge, MA, 15 November 2018.
4. Applications of the CRISPR-Cas system in cancer therapeutics. 10ο Πανελλήνιο Συνέδριο της Εταιρείας Βασικής και Κλινικής Φαρμακολογίας, Ιωάννινα 25-27 Μαΐου 2018.
5. Το Crispr-Cas9 σύστημα: εφαρμογές και περιορισμοί στον καρκίνο. 11ο Σεμινάριο Μοριακής Ογκολογίας και Στοχευμένης Θεραπείας, Ιωάννινα, 30/3-1/4 2017.
6. Η εφαρμογή της ψηφιακής PCR και της αλληλούχισης επόμενης γενιάς στην ανίχνευση του κυκλοφορούντος DNA όγκου. 10ο Σεμινάριο Μοριακής Ογκολογίας και Στοχευμένης Θεραπείας, Βόλος, 25 - 27 Μαρτίου 2016.
7. Επιγενετική του Καρκίνου: Η μεθυλίωση του DNA. 13ο Συνέδριο της Ελληνικής εταιρείας Κλινικής Χημείας-Κλινικής Βιοχημείας, Ηράκλειο Κρήτης, 29-31 Οκτωβρίου 2015.
8. Cancer Epigenetics in the clinical practice. 23ο Συνέδριο Βαλκανικής Ομοσπονδίας Κλινικών Εργαστηρίων, Σεράγεβο, Βοσνία-Ερζεγοβίνη, 8 - 11 Σεπτεμβρίου 2015 (plenary lecture).
9. Επιγενετική απορρύθμιση στον Καρκίνο. 9ο Σεμινάριο Μοριακής Ογκολογίας και Στοχευμένης Θεραπείας, Λευκάδα, 27 - 28 Φεβρουαρίου 2015.
10. Επιγενετική ρύθμιση της γονιδιακής έκφρασης στην υγεία και την ασθένεια: παραδείγματα από το οσφρητικό επιθήλιο και τον καρκίνο του μαστού. Τμήμα Χημείας, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, 26 Μαρτίου 2014.

## XII. MEMBERSHIPS & GRANT REVIEWING ACTIVITIES

| | |
|---|---|
| **2021- today** | Member of the Panhellenic Union of Biosciences. |
| **2019 - 2020** | Member of the American Association for Cancer Research. |
| **2016- today** | Founding member of the Greek Society of study of clonal heterogeneity in neoplasia. |
| **2014 - today** | Member of the Greek Society of Clinical Chemistry and Clinical Biochemistry. |
| **2013 - today** | Member of the Greek Society of Biochemistry and Molecular Biology. |
| **2021** | Evaluator for the French National Cancer Institute. |
| **2020** | Evaluator for the Estonian Research Council. |
| **2019** | Evaluator for IKY post-doctoral fellowships- 2nd round (ESPA 2014-2020). |
| **2019** | Evaluator for "Supporting researcher with the emphasis on young researchers"- 2nd round |